Table 1.
Baseline Participant Characteristics
| Age, y | 65.5 ± 8.6 |
| Range | 37-79 |
| <40 | 2 (3.3) |
| 40-60 | 8 (13.3) |
| >60 | 50 (83.3) |
| Sex | |
| Male | 35 (58.3) |
| Female | 25 (41.7) |
| Ethnicity | |
| White | 54 (90.0) |
| Black | 1 (1.7) |
| Asian | 3 (5.0) |
| Mixed | 2 (3.3) |
| Height, cm | 169 ± 8 |
| Weight, kg | 82.0 ± 19.0 |
| BMI, kg/m2 | 29.1 ± 6.7 |
| Number of statins previously tried | 2 (2-3) |
| 1 | 13 |
| 2 | 24 |
| 3 | 11 |
| 4 | 7 |
| 5 | 5 |
| Previous statin duration, y | 2.84 ± 4.65 1.06 (0.13-3.30) |
| Systolic blood pressure, mm Hg | 139.1 ± 17.3 |
| Diastolic blood pressure, mm Hg | 77.5 ± 8.9 |
| LDL-C, mmol/L | 4.16 ± 1.07 |
| Current indication for statin | |
| Primary prevention | 46 (76.7) |
| Secondary prevention | 14 (23.3) |
| History of diabetes | 4 (7.0) |
| QRISK-2 (18) 10-year risk (primary prevention participants only), % | 24.3 ± 13.6 |
| Number of concomitant medications | 4.72 ± 3.28 |
Values are mean ± SD, n (%), n, or median (interquartile range), unless otherwise indicated.
BMI = body mass index; LDL = low-density lipoprotein.